^Pelletier N, Champagne N, Stifani S, Yang XJ (Apr 2002). "MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2". Oncogene. 21 (17): 2729–40.
doi:
10.1038/sj.onc.1205367.
PMID11965546.
S2CID19597517.
^Mendez R, Delea M, Dain L, Rittler M (January 2020). "A novel pathogenic frameshift variant of KAT6B identified by clinical exome sequencing in a newborn with the Say–Barber–Biesecker–Young–Simpson syndrome". Clinical Dysmorphology. 29 (1): 42–45.
doi:
10.1097/mcd.0000000000000270.
PMID30921092.
S2CID85565150.
Liu C, Lu J, Tan J, Li L, Huang B (2005). "Human interleukin-5 expression is synergistically regulated by histone acetyltransferase CBP/p300 and transcription factors C/EBP, NF-AT and AP-1". Cytokine. 27 (4–5): 93–100.
doi:
10.1016/j.cyto.2004.02.003.
PMID15271374.
Pelletier N, Champagne N, Stifani S, Yang XJ (2002). "MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2". Oncogene. 21 (17): 2729–40.
doi:
10.1038/sj.onc.1205367.
PMID11965546.
S2CID19597517.
^Pelletier N, Champagne N, Stifani S, Yang XJ (Apr 2002). "MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2". Oncogene. 21 (17): 2729–40.
doi:
10.1038/sj.onc.1205367.
PMID11965546.
S2CID19597517.
^Mendez R, Delea M, Dain L, Rittler M (January 2020). "A novel pathogenic frameshift variant of KAT6B identified by clinical exome sequencing in a newborn with the Say–Barber–Biesecker–Young–Simpson syndrome". Clinical Dysmorphology. 29 (1): 42–45.
doi:
10.1097/mcd.0000000000000270.
PMID30921092.
S2CID85565150.
Liu C, Lu J, Tan J, Li L, Huang B (2005). "Human interleukin-5 expression is synergistically regulated by histone acetyltransferase CBP/p300 and transcription factors C/EBP, NF-AT and AP-1". Cytokine. 27 (4–5): 93–100.
doi:
10.1016/j.cyto.2004.02.003.
PMID15271374.
Pelletier N, Champagne N, Stifani S, Yang XJ (2002). "MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2". Oncogene. 21 (17): 2729–40.
doi:
10.1038/sj.onc.1205367.
PMID11965546.
S2CID19597517.